Luke Mountjoy is an Oncology physician affiliated with Colorado Blood Cancer Institute. OpenAlex indexes 76 publications with 939 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1721 E 19th Ave Ste 300
Denver, CO 802181258
Telephone
720-754-4800Provider last certified this registry record 4 Sept 2025.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- Astellas Pharma US IncProgram year20252 payments
- Iovance Biotherapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68.5%CD38-directed Cytolytic Antibody65.6%Daratumumab100%Part B, office-administered≥17 patientsKinase inhibitor1.9%Jakafi69%Tasigna20%Imbruvica11%Part D<11 patients+ 3 more classes in this area
Anti-infectives
14.5%Human Immunoglobulin G10.1%Immune globulin100%Part B, office-administered≥11 patientsShort-acting sulfonamides1.6%Sulfamethoxazole-Trimethoprim100%Part D≥33 patients+ 4 more classes in this area
Metabolism & gastrointestinal
12.2%Osmotically acting laxatives7%Magnesium sulfate96%Magnesium Sulfate4%Part D + Part B<11 patientsSerotonin-3 Receptor Antagonist3.7%Ondansetron hydrochloride100%Part B, office-administered≥16 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Biology of Blood and Marrow Transplantation
2025 - KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”